New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

about

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.

P2860

Q30240043-A4367F8E-BA15-421E-95FB-7041C74210D6

P2860

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

Item

http://www.wikidata.org/entity/Q38924189

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

New strategies in myelofibrosi ...... prognostication and treatment.

@en

type

Item

label

New strategies in myelofibrosi ...... prognostication and treatment.

@en

prefLabel

New strategies in myelofibrosi ...... prognostication and treatment.

@en

P1476

New strategies in myelofibrosi ...... prognostication and treatment.

@en

P2093

Giuseppe Auteri

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

P304

145-150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2324

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Palandri

Michele Baccarani

P577

2016-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27510853

http://www.w3.org/2001/XMLSchema#string

P921

pathogenesis

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

about

P2860

P2860

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921